{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:10:16Z","timestamp":1787688616025,"version":"build-2784847793"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bruton\u2019s tyrosine kinase (BTK) inhibition is one of the treatment standards for patients with relapsed\/refractory Waldenstr\u00f6m\u2019s macroglobulinemia (WM) and for patients with WM who are unsuitable for immunochemotherapy (ICT). It offers deep and durable responses with a manageable safety profile that is generally favorable compared with ICT regimens. However, the limitations of the first approved BTK inhibitor (BTKi), ibrutinib, include reduced efficacy in patients lacking the characteristic WM mutation (<jats:italic>MYD88<\/jats:italic><jats:sup>L265P<\/jats:sup>) and toxicities related to off-target activity. The risk of atrial fibrillation (AF) and other cardiovascular side effects are a notable feature of ibrutinib therapy. Several next-generation covalent BTKis with greater selectivity for BTK are at various stages of development. In November 2021, zanubrutinib became the first of these agents to be approved by the European Medicines Agency for the treatment of WM. Head-to-head trial data indicate that it has comparable efficacy to ibrutinib for patients with WM overall, although it may be more effective in patients with <jats:italic>CXCR4<\/jats:italic> mutations or wild-type <jats:italic>MYD88<\/jats:italic>. In the clinical trial setting, its greater selectivity translates into a reduced risk of cardiovascular side effects, including AF. Acalabrutinib, which is pre-approval in WM, appears to offer similar advantages over ibrutinib in terms of its safety profile. Beyond the next-generation covalent BTKis, non-covalent BTKis are an emerging class with the potential to provide a therapeutic option for patients who relapse on covalent BTKis. In the future, BTKis may be increasingly utilized within combination regimens. Several ongoing trials in WM are investigating the potential for BTKi use in combination with established and novel targeted agents.<\/jats:p>","DOI":"10.1038\/s41375-022-01732-9","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:03:05Z","timestamp":1668855785000},"page":"35-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Managing Waldenstr\u00f6m\u2019s macroglobulinemia with BTK inhibitors"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-9012","authenticated-orcid":false,"given":"Christian","family":"Buske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"1732_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/sonc.2003.50082","volume":"30","author":"RG Owen","year":"2003","unstructured":"Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstr\u00f6m\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia. Semin Oncol. 2003;30:110\u20135.","journal-title":"Semin Oncol"},{"key":"1732_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1732_CR3","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1002\/cncr.26627","volume":"118","author":"H Wang","year":"2012","unstructured":"Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, et al. Temporal and geographic variations of Waldenstr\u00f6m macroglobulinemia incidence: a large population-based study. Cancer. 2012;118:3793\u20133800.","journal-title":"Cancer."},{"key":"1732_CR4","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3","volume":"82","author":"FD Groves","year":"1998","unstructured":"Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr. Waldenstr\u00f6m\u2019s macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer. 1998;82:1078\u201381.","journal-title":"Cancer."},{"key":"1732_CR5","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.V82.10.3148.3148","volume":"82","author":"LJ Herrinton","year":"1993","unstructured":"Herrinton LJ, Weiss NS. Incidence of Waldenstr\u00f6m\u2019s macroglobulinemia. Blood. 1993;82:3148\u201350.","journal-title":"Blood."},{"key":"1732_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3109\/10428194.2012.656103","volume":"53","author":"J Sekhar","year":"2012","unstructured":"Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D. Waldenstr\u00f6m macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma. 2012;53:1625\u20136.","journal-title":"Leuk Lymphoma."},{"key":"1732_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443\u201359.","journal-title":"CA Cancer J Clin"},{"key":"1732_CR8","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","volume":"123","author":"JJ Castillo","year":"2014","unstructured":"Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenstr\u00f6m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014;123:3999\u20134000.","journal-title":"Blood."},{"key":"1732_CR9","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","volume":"100","author":"E Kastritis","year":"2015","unstructured":"Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, et al. Competing risk survival analysis in patients with symptomatic Waldenstr\u00f6m macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica. 2015;100:e446\u2013449.","journal-title":"Haematologica."},{"key":"1732_CR10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjh.15558","volume":"183","author":"L Brandefors","year":"2018","unstructured":"Brandefors L, Melin B, Lindh J, Lundqvist K, Kimby E. Prognostic factors and primary treatment for Waldenstr\u00f6m macroglobulinemia \u2013 a Swedish Lymphoma Registry study. Br J Haematol. 2018;183:564\u201377.","journal-title":"Br J Haematol"},{"key":"1732_CR11","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1016\/S2352-3026(18)30087-5","volume":"5","author":"C Buske","year":"2018","unstructured":"Buske C, Sadullah S, Kastritis E, Tedeschi A, Garc\u00eda-Sanz R, Bolkun L, et al. Treatment and outcome patterns in European patients with Waldenstr\u00f6m\u2019s macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018;5:e299\u2013e309.","journal-title":"Lancet Haematol"},{"key":"1732_CR12","unstructured":"Buske C, Heim D, Herold M, Staber PB, Dreyling M. DGHO-onkopedia guidelines: Waldenstr\u00f6m\u2019s disease (lymphoplasmocytic lymphoma). 2022 [cited; Available from: https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/morbus-waldenstroem-lymphoplasmozytisches-lymphom\/@@guideline\/html\/index.html Accessed May 2022.]"},{"key":"1732_CR13","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol. 2019;74:1667\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"1732_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219\u201332.","journal-title":"Nat Rev Cancer"},{"key":"1732_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41420-022-00927-4","volume":"8","author":"Z Yin","year":"2022","unstructured":"Yin Z, Zou Y, Wang D, Huang X, Xiong S, Cao L, et al. Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease. Cell Death Discov. 2022;8:119.","journal-title":"Cell Death Discov"},{"key":"1732_CR16","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1242\/jcs.071043","volume":"123","author":"HS Kuehn","year":"2010","unstructured":"Kuehn HS, Radinger M, Brown JM, Ali K, Vanhaesebroeck B, Beaven MA, et al. Btk-dependent Rac activation and actin rearrangement following FcepsilonRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci. 2010;123:2576\u201385.","journal-title":"J Cell Sci"},{"key":"1732_CR17","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41423-019-0270-9","volume":"17","author":"S Xia","year":"2020","unstructured":"Xia S, Liu X, Cao X, Xu S. T-cell expression of Bruton\u2019s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Cell Mol Immunol. 2020;17:1042\u201352.","journal-title":"Cell Mol Immunol"},{"key":"1732_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","volume":"72","author":"S Tsukada","year":"1993","unstructured":"Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279\u201390.","journal-title":"Cell."},{"key":"1732_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/361226a0","volume":"361","author":"D Vetrie","year":"1993","unstructured":"Vetrie D, Vorechovsk\u00fd I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226\u201333.","journal-title":"Nature."},{"key":"1732_CR20","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.19.02314","volume":"38","author":"SP Treon","year":"2020","unstructured":"Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, et al. Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020;38:1198\u2013208.","journal-title":"J Clin Oncol"},{"key":"1732_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","volume":"35","author":"LM Kaiser","year":"2021","unstructured":"Kaiser LM, Hunter ZR, Treon SP, Buske C. CXCR4 in Waldenstr\u00f6m\u2019s macroglobulinema: chances and challenges. Leukemia. 2021;35:333\u201345.","journal-title":"Leukemia."},{"key":"1732_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.14196","volume":"175","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenstr\u00f6m Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstr\u00f6m Macroglobulinaemia. Br J Haematol. 2016;175:77\u201386.","journal-title":"Br J Haematol"},{"key":"1732_CR23","unstructured":"Imbruvica 140 mg hard capsules \u2013 summary of product characteristics. Janssen-Cilag International NV; Beerse, Belgium, January 2022."},{"key":"1732_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1200\/JCO.20.00555","volume":"39","author":"SP Treon","year":"2021","unstructured":"Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2021;39:565\u201375.","journal-title":"J Clin Oncol"},{"key":"1732_CR25","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2015;372:1430\u201340.","journal-title":"N Engl J Med"},{"key":"1732_CR26","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J, Garc\u00eda-Sanz R, Macdonald D, Leblond V, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2018;378:2399\u2013410.","journal-title":"N Engl J Med"},{"key":"1732_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.21.00838","volume":"40","author":"C Buske","year":"2022","unstructured":"Buske C, Tedeschi A, Trotman J, Garc\u00eda-Sanz R, MacDonald D, Leblond V, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m\u2019s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022;40:52\u201362.","journal-title":"J Clin Oncol"},{"key":"1732_CR28","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdy146","volume":"29","author":"E Kastritis","year":"2018","unstructured":"Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, et al. Waldenstr\u00f6m\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv41\u2013iv50.","journal-title":"Ann Oncol"},{"key":"1732_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, et al. Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241\u201350.","journal-title":"Lancet Oncol"},{"key":"1732_CR30","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","volume":"36","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Meid K, Gustine JN, Leventoff C, White T, Flynn CA, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstr\u00f6m macroglobulinemia. Leukemia. 2022;36:532\u20139.","journal-title":"Leukemia."},{"key":"1732_CR31","unstructured":"Brukinsa 80 mg hard capsules \u2013 summary of product characteristics. BeiGene Ireland Ltd; January 2022."},{"key":"1732_CR32","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020;136:2038\u201350.","journal-title":"Blood."},{"key":"1732_CR33","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","volume":"4","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4:6009\u201318.","journal-title":"Blood Adv"},{"key":"1732_CR34","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","volume":"7","author":"RG Owen","year":"2020","unstructured":"Owen RG, McCarthy H, Rule S, D\u2019Sa S, Thomas SK, Tournilhac O, et al. Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7:e112\u2013e121.","journal-title":"Lancet Haematol"},{"key":"1732_CR35","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1111\/cas.14561","volume":"111","author":"N Sekiguchi","year":"2020","unstructured":"Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m\u2019s macroglobulinemia. Cancer Sci. 2020;111:3327\u201337.","journal-title":"Cancer Sci"},{"key":"1732_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","volume":"14","author":"D Gu","year":"2021","unstructured":"Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14:40.","journal-title":"J Hematol Oncol"},{"key":"1732_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397:892\u2013901.","journal-title":"Lancet."},{"key":"1732_CR38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.16168","volume":"188","author":"JP Abeykoon","year":"2020","unstructured":"Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenstr\u00f6m macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol. 2020;188:394\u2013403.","journal-title":"Br J Haematol"},{"key":"1732_CR39","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1097\/HS9.0000000000000307","volume":"3","author":"FS Kleijwegt","year":"2019","unstructured":"Kleijwegt FS, Roda AA, Rolvink J, Kater AP, Kersten MJ, Vos JMI. Rare but Serious: Ibrutinib Induced Liver Failure. Hemasphere. 2019;3:e307.","journal-title":"Hemasphere"},{"key":"1732_CR40","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103:874\u20139.","journal-title":"Haematologica."},{"key":"1732_CR41","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.clml.2020.02.001","volume":"20","author":"JM Rhodes","year":"2020","unstructured":"Rhodes JM, LoRe VA 3rd, Mato AR, Chong EA, Barrientos JC, Gerson JN, et al. Ibrutinib-associated Arthralgias\/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. Clin Lymphoma Myeloma Leuk. 2020;20:438\u201344.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1732_CR42","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","volume":"133","author":"DM Stephens","year":"2019","unstructured":"Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298\u2013307.","journal-title":"Blood."},{"key":"1732_CR43","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","volume":"102","author":"I de Weerdt","year":"2017","unstructured":"de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102:1629\u201339.","journal-title":"Haematologica."},{"key":"1732_CR44","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/annonc\/mdp297","volume":"21","author":"S Gill","year":"2010","unstructured":"Gill S, Carney D, Ritchie D, Wolf M, Westerman D, Prince HM, et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol. 2010;21:331\u20134.","journal-title":"Ann Oncol"},{"key":"1732_CR45","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.leukres.2013.05.004","volume":"37","author":"J Lukenbill","year":"2013","unstructured":"Lukenbill J, Kalaycio M. Fludarabine: a review of the clear benefits and potential harms. Leuk Res. 2013;37:986\u201394.","journal-title":"Leuk Res"},{"key":"1732_CR46","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, et al. Ibrutinib-Associated Atrial Fibrillation. JACC Clin Electrophysiol. 2018;4:1491\u20131500.","journal-title":"JACC Clin Electrophysiol"},{"key":"1732_CR47","doi-asserted-by":"publisher","first-page":"e001049","DOI":"10.1136\/openhrt-2019-001049","volume":"6","author":"F Baptiste","year":"2019","unstructured":"Baptiste F, Cautela J, Ancedy Y, Resseguier N, Aurran T, Farnault L, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6:e001049.","journal-title":"Open Heart"},{"key":"1732_CR48","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","volume":"142","author":"L Xiao","year":"2020","unstructured":"Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, et al. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation. 2020;142:2443\u201355.","journal-title":"Circulation."},{"key":"1732_CR49","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0894-7317(99)70105-7","volume":"12","author":"ME Goldman","year":"1999","unstructured":"Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999;12:1080\u20137.","journal-title":"J Am Soc Echocardiogr"},{"key":"1732_CR50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/2040620716654102","volume":"7","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, Palomba ML, Advani R, Treon SP. Ibrutinib in Waldenstr\u00f6m macroglobulinemia: latest evidence and clinical experience. Ther Adv Hematol. 2016;7:179\u201386.","journal-title":"Ther Adv Hematol"},{"key":"1732_CR51","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC); Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373\u2013498.","journal-title":"Eur Heart J"},{"key":"1732_CR52","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739\u201345.","journal-title":"Blood."},{"key":"1732_CR53","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497\u2013506.","journal-title":"Blood."},{"key":"1732_CR54","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/eurheartj\/ehu176","volume":"35","author":"HJ Wellens","year":"2014","unstructured":"Wellens HJ, Schwartz PJ, Lindemans FW, Buxton AE, Goldberger JJ, Hohnloser SH, et al. Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J. 2014;35:1642\u201351.","journal-title":"Eur Heart J"},{"key":"1732_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353\u201363.","journal-title":"Am J Hematol"},{"key":"1732_CR56","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919\u201328.","journal-title":"Blood."},{"key":"1732_CR57","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","volume":"15","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017;15:835\u201347.","journal-title":"J Thromb Haemost"},{"key":"1732_CR58","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/blood.2019000725","volume":"134","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Kastritis E. How I treat Waldenstr\u00f6m macroglobulinemia. Blood. 2019;134:2022\u201335.","journal-title":"Blood."},{"key":"1732_CR59","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood-2018-06-846816","volume":"132","author":"MA Gertz","year":"2018","unstructured":"Gertz MA. Acute hyperviscosity: syndromes and management. Blood. 2018;132:1379\u201385.","journal-title":"Blood."},{"key":"1732_CR60","first-page":"1088","volume":"130","author":"JJ Castillo","year":"2017","unstructured":"Castillo JJ, Gustine J, Meid K, Dubeau T, Severns P, Treon SP. Acquired Von Willebrand disease in Patients with Waldenstr\u00f6m Macroglobulinemia. Blood. 2017;130:1088.","journal-title":"Blood."},{"key":"1732_CR61","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","volume":"124","author":"M Levade","year":"2014","unstructured":"Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124:3991\u20135.","journal-title":"Blood."},{"key":"1732_CR62","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/leu.2014.247","volume":"29","author":"S Kamel","year":"2015","unstructured":"Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29:783\u20137.","journal-title":"Leukemia."},{"key":"1732_CR63","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","volume":"103","author":"JJ Castillo","year":"2018","unstructured":"Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Treon SP. Ibrutinib withdrawal symptoms in patients with Waldenstr\u00f6m macroglobulinemia. Haematologica. 2018;103:e307\u2013e310.","journal-title":"Haematologica."},{"key":"1732_CR64","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.3324\/haematol.2018.191999","volume":"103","author":"JJ Castillo","year":"2018","unstructured":"Castillo JJ, Gustine JN, Meid K, Dubeau TE, Xu L, Yang G, et al. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstr\u00f6m macroglobulinemia. Haematologica. 2018;103:e466\u2013e468.","journal-title":"Haematologica."},{"key":"1732_CR65","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/bloodadvances.2019000640","volume":"3","author":"G Dobie","year":"2019","unstructured":"Dobie G, Kuriri FA, Omar MMA, Alanazi F, Gazwani AM, Tang CPS, et al. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin \u03b1IIb\u03b23 in mice and humans. Blood Adv. 2019;3:4298\u2013311.","journal-title":"Blood Adv"},{"key":"1732_CR66","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","volume":"6","author":"CS Tam","year":"2022","unstructured":"Tam CS, Dimopoulos M, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6:1296\u2013308.","journal-title":"Blood Adv"},{"key":"1732_CR67","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1038\/s41375-020-0987-6","volume":"34","author":"DA Bond","year":"2020","unstructured":"Bond DA, Huang Y, Fisher JL, Ruppert AS, Owen DH, Bertino EM, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 2020;34:3197\u2013205.","journal-title":"Leukemia."},{"key":"1732_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2019-128404","volume":"134","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Banerji V, Fogliatto LM, Herishanu Y, Munir T, Walewska R, et al. ELEVATE TN: Phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). Blood. 2019;134:31.","journal-title":"Blood."},{"key":"1732_CR69","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","volume":"1","author":"AP Bye","year":"2017","unstructured":"Bye AP, Unsworth AJ, Desborough MJ, Hildyard CAT, Appleby N, Bruce D, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2017;1:2610\u201323.","journal-title":"Blood Adv"},{"key":"1732_CR70","doi-asserted-by":"publisher","first-page":"668162","DOI":"10.3389\/fonc.2021.668162","volume":"11","author":"HA Abbas","year":"2021","unstructured":"Abbas HA, Wierda WG. Acalabrutinib: a selective bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Front Oncol. 2021;11:668162.","journal-title":"Front Oncol"},{"key":"1732_CR71","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/17474086.2018.1473030","volume":"11","author":"FT Awan","year":"2018","unstructured":"Awan FT, Jurczak W. Use of acalabrutinib in patients with mantle cell lymphoma. Expert Rev Hematol. 2018;11:495\u2013502.","journal-title":"Expert Rev Hematol"},{"key":"1732_CR72","unstructured":"Calquence 100 mg hard capsules \u2013 summary of product characteristics. AstraZeneca UK Limited; December 2021."},{"key":"1732_CR73","doi-asserted-by":"publisher","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupinan","year":"2021","unstructured":"Estupinan HY, Berglof A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942.","journal-title":"Front Cell Dev Biol"},{"key":"1732_CR74","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/HS9.0000000000000222","volume":"3","author":"A Tedeschi","year":"2019","unstructured":"Tedeschi A, Frustaci AM. Waldenstr\u00f6m\u2019s macroglobulinemia front line treatment. Hemasphere. 2019;3:62\u20134.","journal-title":"Hemasphere"},{"key":"1732_CR75","doi-asserted-by":"publisher","first-page":"e19506","DOI":"10.1200\/JCO.2021.39.15_suppl.e19506","volume":"39","author":"M Shadman","year":"2021","unstructured":"Shadman M, Sharman JP, Levy MY, Porter R, Zafar SF, Burke JM, et al. Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and\/or acalabrutinib. J Clin Oncol. 2021;39:e19506.","journal-title":"J Clin Oncol"},{"key":"1732_CR76","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","volume":"57","author":"AD Buhimschi","year":"2018","unstructured":"Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman AM, et al. Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation. Biochemistry. 2018;57:3564\u201375.","journal-title":"Biochemistry."},{"key":"1732_CR77","doi-asserted-by":"publisher","first-page":"e127566","DOI":"10.1172\/jci.insight.127566","volume":"4","author":"S Wang","year":"2019","unstructured":"Wang S, Mondal S, Zhao C, Berishaj M, Ghanakota P, Batlevi CL, et al. Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. JCI Insight. 2019;4:e127566.","journal-title":"JCI Insight"},{"key":"1732_CR78","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","volume":"35","author":"HY Estupinan","year":"2021","unstructured":"Estupinan HY, Wang Q, Berglof A, Schaafsma GCP, Shi Y, Zhou L, et al. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia. 2021;35:1317\u201329.","journal-title":"Leukemia."},{"key":"1732_CR79","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","volume":"13","author":"SP Treon","year":"2007","unstructured":"Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, et al. Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstr\u00f6m\u2019s macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007;13:3320\u20135.","journal-title":"Clin Cancer Res"},{"key":"1732_CR80","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","volume":"28","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2010;28:1422\u20138.","journal-title":"J Clin Oncol"},{"key":"1732_CR81","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.21.01194","volume":"40","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, et al. Venetoclax in previously treated Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2022;40:63\u201371.","journal-title":"J Clin Oncol"},{"key":"1732_CR82","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/blood-2019-121936","volume":"134","author":"ND Wagner-Johnston","year":"2019","unstructured":"Wagner-Johnston ND, Schuster SJ, de Vos S, Salles GA, Jurczak W, Rajakumaraswamy N, et al. Long-term follow-up of idelalisib monotherapy in patients with double-refractory marginal zone lymphoma or lymphoplasmacytic lymphoma\/ Waldenstr\u00f6m\u2019s macroglobulinemia. Blood. 2019;134:4006.","journal-title":"Blood."},{"key":"1732_CR83","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/bloodadvances.2020003895","volume":"5","author":"C Tomowiak","year":"2021","unstructured":"Tomowiak C, Poulain S, Herbaux C, Perrot A, Mahe B, Morel P, et al. Obinutuzumab and idelalisib in symptomatic patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia. Blood Adv. 2021;5:2438\u201346.","journal-title":"Blood Adv"},{"key":"1732_CR84","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","volume":"28","author":"C Kyriakou","year":"2010","unstructured":"Kyriakou C, Canals C, Cornelissen JJ, Socie G, Willemze R, Ifrah N, et al. Allogeneic stem-cell transplantation in patients with Waldenstr\u00f6m macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4926\u201334.","journal-title":"J Clin Oncol"},{"key":"1732_CR85","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","volume":"28","author":"C Kyriakou","year":"2010","unstructured":"Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstr\u00f6m macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:2227\u201332.","journal-title":"J Clin Oncol"},{"key":"1732_CR86","doi-asserted-by":"publisher","first-page":"e004128","DOI":"10.1136\/jitc-2021-004128","volume":"10","author":"ML Palomba","year":"2022","unstructured":"Palomba ML, Qualls D, Monette S, Sethi S, Dogan A, Roshal M, et al. CD19-directed chimeric antigen receptor T cell therapy in Waldenstr\u00f6m macroglobulinemia: a preclinical model and initial clinical experience. J Immunother Cancer. 2022;10:e004128.","journal-title":"J Immunother Cancer"},{"key":"1732_CR87","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/10428194.2019.1665668","volume":"61","author":"R Bansal","year":"2020","unstructured":"Bansal R, Jurcic JG, Sawas A, Mapara MY, Reshef R. Chimeric antigen receptor T cells for treatment of transformed Waldenstr\u00f6m macroglobulinemia. Leuk Lymphoma. 2020;61:465\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1732_CR88","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/jpm11050355","volume":"11","author":"R Salvaris","year":"2021","unstructured":"Salvaris R, Ong J, Gregory GP. Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas. J Pers Med. 2021;11:355.","journal-title":"J Pers Med"},{"key":"1732_CR89","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.3324\/haematol.2014.119669","volume":"100","author":"M Borge","year":"2015","unstructured":"Borge M, Bel\u00e9n Almej\u00fan M, Podaza E, Colado A, Fern\u00e1ndez Grecco H, Cabrejo M, et al. Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica. 2015;100:e140\u20132.","journal-title":"Haematologica."},{"key":"1732_CR90","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1158\/2326-6066.CIR-18-0319","volume":"6","author":"KR VanDerMeid","year":"2018","unstructured":"VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS. Cellular cytotoxicity of next-generation CD20 monoclonal antibodies. Cancer Immunol Res. 2018;6:1150\u201360.","journal-title":"Cancer Immunol Res"},{"key":"1732_CR91","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.3324\/haematol.2019.220590","volume":"105","author":"TWH Flinsenberg","year":"2020","unstructured":"Flinsenberg TWH, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia KYT, et al. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica. 2020;105:e76\u20139.","journal-title":"Haematologica."},{"key":"1732_CR92","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/bloodadvances.2020002183","volume":"4","author":"CS Tam","year":"2020","unstructured":"Tam CS, Quach H, Nicol A, Badoux X, Rose H, Prince HM, et al. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv. 2020;4:4802\u201311.","journal-title":"Blood Adv"},{"key":"1732_CR93","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278\u201391.","journal-title":"Lancet."},{"key":"1732_CR94","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39:3853\u201365.","journal-title":"J Clin Oncol"},{"key":"1732_CR95","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood.2020006449","volume":"136","author":"J Trotman","year":"2020","unstructured":"Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G, et al. Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up. Blood. 2020;136:2027\u201337.","journal-title":"Blood"},{"key":"1732_CR96","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35:312\u201332.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01732-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01732-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01732-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T11:04:31Z","timestamp":1674990271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01732-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1732"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01732-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"10 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CB declares honoraria from Roche, Pfizer, Janssen, Hexal, Celltrion, AbbVie, Novartis, Bayer, Morphosys, Regeneron, Beigene; and research funding from Roche, Janssen, Celltrion, AbbVie, Bayer, Amgen, and MSD. WJ declares honoraria and consultancy fees from AstraZeneca, BeiGene, and Janssen. JES declares consultancy fees and research grants from AstraZeneca, BeiGene, BMS, and Novartis. MD declares honoraria and consultancy fees from Amgen, BeiGene, Janssen, Celgene\/Genesis, Sanofi, Takeda, Karyopharm, and GSK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}